MedTrace Logo

Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and Tadalafil

NCT03240939 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2017-11-24

No results posted yet for this study

Summary

A randomized, open label, single dose, two-way crossover clinical trial to investigate the pharmacokinetics and safety/tolerability of YY-201 in comparison to Dutasteride and Tadalafil administered in healthy male volunteers

Conditions

  • Benign Prostatic Hyperplasia

Interventions

DRUG

Dutasteride 0.5 mg

single dose

DRUG

Tadalafil 5 mg

single dose

DRUG

YY-201

single dose

Sponsors & Collaborators

  • Yuyu Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Hyeong-Seok Lim, M.D.,Ph.D. · Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-27
Primary Completion
2017-07-07
Completion
2017-10-10

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03240939 on ClinicalTrials.gov